Log in
Enquire now
‌

US Patent 11198731 Combinations of cabozantinib and atezolizumab to treat cancer

Patent 11198731 was granted and assigned to Exelixis Ltd on December, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Currently, there are no issues on this topic.

Find more entities like US Patent 11198731 Combinations of cabozantinib and atezolizumab to treat cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo